NASDAQ:AGEN - Agenus Stock Price, Forecast & News

Agenus' stock was trading at $2.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AGEN stock has decreased by 13.6% and is now trading at $2.35. View which stocks have been mosted impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Agenus.

Agenus is scheduled to release its next quarterly earnings announcement on Friday, May 8th 2020. View our earnings forecast for Agenus.

Agenus Inc (NASDAQ:AGEN) issued its earnings results on Thursday, March, 12th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.16. The biotechnology company had revenue of $34.50 million for the quarter, compared to the consensus estimate of $17.05 million. View Agenus' earnings history.

1 equities research analysts have issued 12-month price objectives for Agenus' stock. Their forecasts range from $6.00 to $6.00. On average, they expect Agenus' share price to reach $6.00 in the next year. This suggests a possible upside of 155.3% from the stock's current price. View analysts' price targets for Agenus.

News articles about AGEN stock have been trending very negative on Saturday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Agenus earned a news impact score of -3.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View the latest news aboutAgenus.

Agenus saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 13,020,000 shares, an increase of 7.2% from the February 13th total of 12,150,000 shares. Based on an average daily trading volume, of 1,720,000 shares, the short-interest ratio is presently 7.6 days. Currently, 12.4% of the company's shares are short sold. View Agenus' Current Options Chain.

Some companies that are related to Agenus include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include Rosetta Genomics (ROSG), Exelixis (EXEL), REDHILL BIOPHAR/S (RDHL), Merrimack Pharmaceuticals (MACK), Opko Health (OPK), Gilead Sciences (GILD), Novavax (NVAX), Energy Transfer LP Unit (ET), AcelRx Pharmaceuticals (ACRX) and Inovio Pharmaceuticals (INO).

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Agenus' stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (2.86%), Oracle Investment Management Inc. (2.02%), Geode Capital Management LLC (1.10%), Panagora Asset Management Inc. (0.69%), Charles Schwab Investment Management Inc. (0.52%) and Bank of New York Mellon Corp (0.34%). View institutional ownership trends for Agenus.

AGEN stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Chicago Equity Partners LLC, Bank of America Corp DE, Charles Schwab Investment Management Inc., Strs Ohio, New York State Common Retirement Fund, Zurcher Kantonalbank Zurich Cantonalbank, and Bank of New York Mellon Corp. View insider buying and selling activity for Agenus.

AGEN stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Oracle Investment Management Inc., Captrust Financial Advisors, Renaissance Technologies LLC, Connor Clark & Lunn Investment Management Ltd., Connor Clark & Lunn Investment Management Ltd., Acadian Asset Management LLC, and Hussman Strategic Advisors Inc.. View insider buying and selling activity for Agenus.

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AGEN stock can currently be purchased for approximately $2.35.

Agenus has a market capitalization of $379.74 million and generates $150.05 million in revenue each year. The biotechnology company earns $-107,660,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Agenus employs 294 workers across the globe. View additional information about Agenus.

The official website for Agenus is http://agenusbio.com/.

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]